profit from every $100 of sales.
$0$100
Abeona Therapeutics
$2.30-6.31% today
-44.8% in 1 year
1-year low $2.301-year high $7.46
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $1.99 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Abeona Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $1.41 million in 2022 to $5.82 million in 2025, with $71.2 million of profit last year.
SalesProfit
Abeona Therapeutics vs. similar companies
Abeona Therapeutics grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Abeona Therapeutics | 2.0× · Cheap | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Abeona Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 4 | 0 | 6 | |
| 1 | 2 | 0 | 2 | |
| -45 | -48 | -64 | -89 | |
| -34 | -51 | -57 | 79 | |
| -40 | -54 | -64 | 71 | |
| -5.53 | -2.53 | -1.55 | 1.01 | |
| 68.2% | 54.1% | – | 41.2% | |
| -3,200.6% | -1,377.1% | – | -1,536.9% | |
| -2,807.4% | -1,548.2% | – | 1,223.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 64 | 64 | 109 | 220 |
| Cash | 14 | 14 | 23 | 78 |
| Total debt | 8 | 5 | 23 | 25 |
| Total liabilities | 37 | 49 | 65 | 60 |
| 27 | 15 | 44 | 159 | |
| 8 | 21 | 41 | 66 | |
| -89.5% | -210.0% | -70.1% | 32.2% | |
| -148.3% | -365.5% | -144.7% | 44.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -43 | -37 | -56 | -76 | |
| 0 | 0 | 2 | 8 | |
| -44 | -37 | -58 | -84 | |
| Dividends paid | – | – | – | – |
| 26 | 0 | – | – | |
| 3 | 5 | 7 | 11 |
Valuation
- 2.0×
- –
- –
- 2.1×
- 24.4×
- –
- 1.1×
- -59.5%
- 50.2%
- 0.0%
Profitability
- 41.2%
- -1,536.9%
- 1,223.1%
- 458.3%
- -50.9%
- -120.8%
- 41.4%
- 33.3%
- -55.4%
- 181.7%
Growth
- +60.3%
- –
- −44.2%
- –
- +91.5%
Financial health
- -0.6×
- 0.16
- 11.7%
- -26.0×
- 5.89
- 5.70
- 0.07
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 6%of 958
Top 1%of 600
Top 9%of 889
Bottom 1%of 987
What analysts expect
- Average price target
- $17.00
- Range
- $17.00 – $17.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.30 | -0.33 | +9.1% |
| Mar 17, 2026 | -0.34 | -0.35 | +2.9% |
| Nov 12, 2025 | -0.10 | -0.27 | +63.0% |
| Aug 14, 2025 | 1.71 | -0.39 | +538.5% |
| May 15, 2025 | -0.24 | -0.35 | +31.4% |
| Mar 20, 2025 | -0.24 | -0.43 | +44.2% |
| Nov 14, 2024 | -0.31 | -0.38 | +18.4% |
| Aug 12, 2024 | -0.75 | -0.33 | −127.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
44No pass
Benjamin Graham
70Pass
Philip Fisher
51No pass
Peter Lynch
100Pass
Joel Greenblatt
62Pass
Charlie Munger
42No pass
Terry Smith
38No pass
Questions about Abeona Therapeutics
Is Abeona Therapeutics a good stock to buy?
A strong, very profitable business, and the price looks low. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Abeona Therapeutics AI analysis
What does Abeona Therapeutics do?
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. It is in Biotechnology.
Does Abeona Therapeutics pay a dividend?
No. Abeona Therapeutics does not pay a dividend at the moment.
Is Abeona Therapeutics stock halal?
No. Abeona Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 55% of its market value, at or above the 33% limit. How we check
How has Abeona Therapeutics stock done over the past year?
Down 44.8% over the past twelve months, to $2.30. It traded between $2.30 and $7.46 and is 69.2% below its high.
Who are Abeona Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Abeona Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.